Articles
	Summary of Product Trials for 10,164 Patients Gregory J. Schears INS Vol. 29, No. 4 July/August 2006 Inadequate catheter securement is an under-recognized patient safety issue that contributes significantly to catheter-related complications, including dislodgement, occlusion, infiltration, and infection. Pooled data from prospective product trials at 83 hospitals compared tape to a standard peripheral intravenous(PIV) securement method with a PIV-specific catheter-stabilizing device (Statlock). A 67% reduction (P<.001) in total patient complications was observed in the stabilizing device group, as compared with the tape group. Also the need for unscheduled PIV restarts was reduced by 76% with the stabilizing device (p< .001). An annual cost savings of $18,000 oer hospital on PIV materials and a combined savings of $277,000 on materials, complication costs, and nursing time were estimated on the basis of these reduced complications. Newer catheter-stabilizing technologies can help to reduce patient complications, for an overall cost savings, and consequently reduce needlestick exposures for healthcare providers by reducing restarts and prolonging dwell times.
	The Advantages of a Precision-engineered Securement Device for Fixation of Arterial Pressure-monitoring Catheters Catharine Stephenson, RN BSN Journal of the Association for Vascular Access Fall 2005 This prospective, controlled study was conducted to evaluate the clinical and cost consequences of securing arterial catheters with StatLock Arterial Select compared with tape and transparent membrane dressing. The study clearly demonstrates that not only did StatLock significantly reduce unscheduled arterial catheter restarts by 49%, but it also resulted in improved clinical outcomes and enhanced healthcare worker protection at, essentially, no added cost. In fact, at today's reduced pricing, StatLock would have resulted in considerable cost savings.
	What Works: Catheter Securement Device Provides Substantial Cost Savings Robert Inbornone Healthcare Purchasing News June 2005 Health First, Inc. of Rockledge, Fla. had a problem: Implementation of the CDC-approved 96-hour protocol for duration of peripheral IVs (PIVs) was costing them time and money. Since only 8-15% of tape-secured PIVs were making it to 72 hours, the percent PIV survival to 96 hours was even less. Nurses were running up and down the halls at all hours to gather the necessary items to restart virtually all their PIVs. After an extensive cost and clinical analysis, the health system decided StatLock IV Ultra was the solution. As this article by the Corporate Director of Contract and Supply Chain Administration makes clear: StatLock IV is the only proven, cost-efficient technology that allows for successful implementation of the CDC's 96-hour PIV protocol.

© 2007 C.R. Bard, Inc. All rights reserved.